In short
Ioflupane (123I), also known as DaTSCAN™, is a radioactive drug being studied in clinical trials for its potential in diagnosing Parkinsonian syndromes. These trials aim to evaluate the safety, effectiveness, and diagnostic capabilities of Ioflupane (123I) when used in Single Photon Emission Computed Tomography (SPECT) imaging. The studies involve both healthy volunteers and patients with various movement disorders, focusing on the drug's ability to detect striatal dopaminergic deficits associated with conditions like Parkinson's disease.
At a glance
- Drug Name
- Ioflupane (123I), also known as DaTSCAN™
- Administration
- Single intravenous injection, 111-185 MBq
- Imaging Technique
- Single Photon Emission Computed Tomography (SPECT)
- Target Conditions
- Parkinsonian syndromes, including Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
- Control Groups
- Essential tremor patients and healthy volunteers
- Primary Outcomes
- Safety assessment, biodistribution, radiation dosimetry, diagnostic efficacy
- Secondary Outcomes
- Striatal uptake analysis, adverse events monitoring
- Safety Monitoring
- Adverse events, vital signs, physical examinations, laboratory tests, ECG
- Image Analysis
- Blinded independent reads, semi-quantitative assessment using DaTQUANT™
What is IOFLUPANE (123I)?
IOFLUPANE (123I), also known by its brand name DaTSCAN™, is a specialized diagnostic tool used in medical imaging. It's not a treatment or cure for any disease, but rather a substance that helps doctors visualize certain parts of the brain to aid in diagnosis. This radioactive medication is used in a type of scan called Single Photon Emission Computed Tomography (SPECT).
How Does IOFLUPANE (123I) Work?
IOFLUPANE (123I) works by attaching to structures in the brain called dopamine transporters. These transporters are found in areas of the brain that control movement. In certain neurological conditions, the number of these transporters decreases. When IOFLUPANE (123I) is injected into the body, it travels to the brain and binds to these transporters. Special cameras can then detect where the IOFLUPANE (123I) has accumulated, creating images that show the distribution of dopamine transporters in the brain.
What Conditions Does IOFLUPANE (123I) Help Diagnose?
IOFLUPANE (123I) is primarily used to help diagnose a group of conditions known as Parkinsonian Syndromes. These include:
- Parkinson's Disease (PD): A progressive disorder that affects movement, balance, and coordination.
- Multiple System Atrophy (MSA): A rare condition that causes symptoms similar to Parkinson's disease but with more widespread effects on the body.
- Progressive Supranuclear Palsy (PSP): A brain disorder that causes serious problems with walking, balance, and eye movements.
IOFLUPANE (123I) can also help differentiate these conditions from Essential Tremor, a neurological disorder that causes rhythmic shaking.
How is IOFLUPANE (123I) Administered?
IOFLUPANE (123I) is given as a single intravenous (IV) injection into a vein in the arm. The dose is carefully calculated based on the patient's needs, but typically ranges from 111 to 185 megabecquerels (MBq). This may sound like a complex term, but it simply refers to the amount of radioactive material in the injection. The maximum volume of the injection is usually 5 milliliters (mL).
Imaging Process
After receiving the IOFLUPANE (123I) injection, patients undergo SPECT imaging. This usually occurs between 3 to 6 hours after the injection and can last anywhere from 20 minutes to 1 hour. During this time, special cameras take pictures of the brain to show where the IOFLUPANE (123I) has accumulated.
Safety and Side Effects
As with any medical procedure, safety is a top priority when using IOFLUPANE (123I). Researchers closely monitor patients for any adverse events (unwanted side effects). These can range from mild issues like discomfort at the injection site to more serious events. However, it's important to note that serious side effects are rare.
After receiving IOFLUPANE (123I), patients are monitored for changes in various health indicators, including:
- Vital signs (blood pressure, heart rate, temperature, respiratory rate)
- Blood tests
- Urine tests
- Physical examinations
- Electrocardiogram (ECG) to check heart function
Patients also complete questionnaires about how they feel after the injection.
Ongoing Research
Scientists continue to study IOFLUPANE (123I) to better understand how it works in different populations. For example, recent studies have looked at its use in Chinese patients and healthy volunteers. These studies help researchers understand how the medication is distributed in the body, how it's eliminated, and what radiation doses different organs receive.
This ongoing research helps to ensure that IOFLUPANE (123I) remains a safe and effective tool for diagnosing Parkinsonian Syndromes and differentiating them from conditions like Essential Tremor.